Sorafenib for Patients with Advanced Angiosarcoma Full Text
The Oncologist, 02/27/2012
Clinical Article
Ray–Coquard I et al. – Sorafenib showed limited antitumor activity in pretreated patients only, for both visceral and superficial angiosarcoma, but tumor control was of short duration.



